Prenatal DNA Sequencing Global Market Report 2024

The prenatal dna sequencing market size has grown rapidly in recent years. It will grow from $2.23 billion in 2023 to $2.56 billion in 2024 at a compound annual growth rate (CAGR) of 14.7%. The growth observed in the historical period can be attributed to changes in patient preferences, advancements and research in the medical field, increased adoption of non-invasive testing, a rise in maternal age, and enhancements in the accuracy and reliability of prenatal DNA sequencing.

The prenatal dna sequencing market size is expected to see rapid growth in the next few years. It will grow to $4.56 billion in 2028 at a compound annual growth rate (CAGR) of 15.5%. The anticipated growth in the forecast period can be attributed to consumer demand for early detection, an increase in maternal age and associated pregnancy risks, public health initiatives, support from regulatory bodies and adherence to guidelines, and advancements in data analysis. Noteworthy trends expected in the forecast period include intensified research and development efforts, considerations related to ethics and regulatory frameworks, enhancements in data interpretation tools, integration of precision medicine, and the promotion of prenatal genetic counseling.

The anticipated rise in cancer prevalence is set to drive the growth of the prenatal DNA sequencing market. Cancer, characterized by uncontrolled cell growth and spread, prompts the use of prenatal DNA sequencing to detect fetal aneuploidy and identify cancer in the fetus. This sequencing method unveils inherited or germline DNA changes influencing a person's cancer susceptibility. For example, data from the American Cancer Society in January 2023 showed an increase in cancer cases from 1,898,160 in 2021 to 1,958,310 in 2023, reflecting a growth rate of 3.16%. Consequently, the prevalence of cancer acts as a driving force for the prenatal DNA sequencing market.

The expected increase in the birth rate is poised to contribute to the growth of the prenatal DNA sequencing market. Birth rate, indicating the number of live births per 1,000 people in a specified population and time period, aligns with the use of prenatal DNA sequencing to identify genetic abnormalities in unborn fetuses. This aids in making informed reproductive decisions and implementing selective interventions during birth. In May 2022, the Centers for Disease Control and Prevention (CDC) reported a 1% rise in U.S. births compared to 2020, reaching a total of 3,659,289 births in 2021. The overall fertility rate for 2021 also increased by 1%, standing at 56.6 births per 1,000 women aged 15-44. Thus, the higher birth rate acts as a driving factor for the prenatal DNA sequencing market.

Product innovation is a prominent trend in the prenatal DNA sequencing market, with major companies concentrating on developing innovative solutions to enhance their market standing. Juno Diagnostics, Inc., a U.S.-based health technology company, introduced the noninvasive prenatal screening test 'Hazel' in November 2022. Designed with no risk of miscarriage, the test can be performed as early as 9 weeks into pregnancy using a small blood sample. It screens for common genetic conditions such as Down syndrome, Edwards syndrome, and Patau syndrome.

Major companies in the prenatal DNA sequencing market are actively developing compliance solutions, such as CE-IVD compliance solutions, to offer a next-generation sequencing approach to noninvasive prenatal testing (NIPT). Illumina, a U.S.-based life science tools developer, partnered with Next Generation Genomic in June 2021 to launch VeriSeq NIPT Solution v2 in Thailand. This CE-IVD next-generation sequencing-based approach expands prenatal screening beyond common aneuploidies to rare autosomal aneuploidies, sex chromosome aneuploidies, and large partial duplications and deletions.

In November 2022, Myriad Genetics, Inc., a U.S.-based provider of genetic testing and precision medicine, acquired Gateway Genomics, LLC, a personal genomics and prenatal DNA company. The undisclosed acquisition is expected to enhance Myriad's women's health product portfolio and provide access to personalized genetic tests, strengthening its position in the market.

Major companies operating in the prenatal dna sequencing market report are Agilent Technologies Inc., BGI Group, F. Hoffmann-La Roche Ltd, Illumina Inc., Laboratory Corporation of America Holdings, Natera Inc., Genomic Health Inc., Myriad Genetics Inc., Invitae Corporation, PerkinElmer Inc., Macrogen Inc., Pacific Biosciences of California Inc., Genewiz LLC, 10x Genomics Inc., Oxford Nanopore Technologies Limited, Thermo Fisher Scientific Inc., Berry Genomics Co. Ltd., Centrillion Technology Holdings Corp., Cynvenio Biosystems Inc., Eurofins LifeCodexx AG, Fluidigm Corp., GATC Biotech AG, GeneDx Inc., Genoma SA, Good Start Genetics Inc., Helix OpCo LLC, Igenomix S.L., Integrated DNA Technologies Inc., KellBenx Inc., LifeCodexx AG.

North America was the largest region in the prenatal DNA sequencing market in 2023. The regions covered in the prenatal dna sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the prenatal dna sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of prenatal DNA sequencing encompass genetic diseases and nonhereditary diseases. Genetic diseases refer to disorders or diseases caused by mutations in one or more genes. DNA sequencing plays a crucial role in determining whether a gene carries a mutation leading to a specific disorder. Applications of prenatal DNA sequencing include conditions such as hemophilia, Down syndrome, cystic fibrosis, autism, DiGeorge syndrome, AIDS, cancer, and others. Various users, including academic research, clinical research, hospitals and clinics, as well as pharmaceutical and biotechnology companies, employ this technology.

The prenatal DNA sequencing market research report is one of a series of new reports that provides prenatal DNA sequencing market statistics, including the prenatal DNA sequencing industry global market size, regional shares, competitors with a prenatal DNA sequencing market share, detailed prenatal DNA sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the prenatal DNA sequencing industry. This prenatal DNA sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.